Bora CDMO Bora CDMO

X

Find Drugs in Development News & Deals for Lenvatinib Mesylate

PharmaCompass
API SUPPLIERS
API Suppliers

API Suppliers

US DMFs Filed

US DMFs Filed

CEP/COS Certifications

CEP/COS Certifications

0

JDMFs Filed

JDMFs Filed

0

Other Certificates

Other Certificates

Other Suppliers

Other Suppliers

API REF. PRICE (USD / KG)

0

INTERMEDIATES
DOSSIERS // FDF
USA (Orange Book)

USA (Orange Book)

Europe

Europe

Canada

Canada

Australia

Australia

0

South Africa

South Africa

0

Uploaded Dossiers

Uploaded Dossiers

0

GLOBAL SALES (USD Million)

U.S. Medicaid

Annual Reports

0

EXCIPIENTS

0

PATENTS & EXCLUSIVITIES

USFDA Orange Book Patents

USFDA Exclusivities

DIGITAL CONTENT

Blog #PharmaFlow

0

News

REF STANDARD

EDQM

0

USP

0

JP

0

Other Listed Suppliers

0

SERVICES

0

Details:

CS1003 (nofazinlimab) is a humanized recombinant IgG4 monoclonal antibody targeting human programmed cell death protein 1 (PD-1) being developed in combination with lenvatinib as first-line treatment for patients with advanced hepatocellular carcinoma.


Lead Product(s): Nofazinlimab,Lenvatinib Mesylate

Therapeutic Area: Oncology Product Name: CS1003

Highest Development Status: Phase IIIProduct Type: Large molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable March 18, 2022

ASK
US
PHARMACOMPASS
Upload
your Marketing & Sales content

Details:

MHLW has approved the combination of LENVIMA (lenvatinib) multiple receptor tyrosine kinase inhibitor Plus KEYTRUDA® (pembrolizumab) anti-PD-1 therapy for the treatment of patients with endometrial carcinoma.


Lead Product(s): Lenvatinib Mesylate,Pembrolizumab

Therapeutic Area: Oncology Product Name: Lenvima

Highest Development Status: ApprovedProduct Type: Small molecule

Partner/Sponsor/Collaborator: Merck & Co

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable December 24, 2021

ASK
US
PHARMACOMPASS
Upload
your Marketing & Sales content

Details:

KEYTRUDA plus LENVIMA is the first anti-PD-1 and tyrosine kinase inhibitor combination to demonstrate a survival benefit in advanced endometrial carcinoma patients, and the benefit was shown regardless of mismatch repair status.


Lead Product(s): Lenvatinib Mesylate,Pembrolizumab

Therapeutic Area: Oncology Product Name: Lenvima

Highest Development Status: ApprovedProduct Type: Small molecule

Partner/Sponsor/Collaborator: Eisai

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable October 15, 2021

ASK
US
PHARMACOMPASS
Upload
your Marketing & Sales content

Details:

In this trial, LENVIMA plus KEYTRUDA showed a statistically significant and clinically meaningful improvement in the primary endpoints of Progression-Free Survival and Overall Survival as well as the secondary endpoint of Objective Response Rate versus chemotherapy.


Lead Product(s): Lenvatinib Mesylate,Pembrolizumab

Therapeutic Area: Oncology Product Name: Lenvima

Highest Development Status: Phase IIIProduct Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable April 23, 2021

ASK
US
PHARMACOMPASS
Upload
your Marketing & Sales content

Details:

The application requesting an indication of lenvatinib in combination with pembrolizumab for RCC is based on the results of the pivotal Phase 3 CLEAR study (Study 307/KEYNOTE-581) for the first-line treatment of patients with advanced RCC.


Lead Product(s): Lenvatinib Mesylate,Pembrolizumab

Therapeutic Area: Oncology Product Name: Lenvima

Highest Development Status: ApprovedProduct Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable March 30, 2021

ASK
US
PHARMACOMPASS
Upload
your Marketing & Sales content

Details:

The pivotal Phase 3 Study 309/KEYNOTE-775 evaluated LENVIMA in combination with KEYTRUDA® in patients with advanced endometrial cancer, following at least one prior platinum-based regimen in Japan, the United States, Europe and other countries.


Lead Product(s): Lenvatinib Mesylate,Pembrolizumab

Therapeutic Area: Oncology Product Name: Lenvima

Highest Development Status: Phase IIIProduct Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable March 15, 2021

ASK
US
PHARMACOMPASS
Upload
your Marketing & Sales content

Details:

Bdfoie (lenvatinib mesylate), an oral receptor tyrosine kinase inhibitor, launched in India, for the treatment of differentiated thyroid cancer, advanced liver cancer and advanced kidney cancer.


Lead Product(s): Lenvatinib Mesylate

Therapeutic Area: Oncology Product Name: Bdfoie

Highest Development Status: ApprovedProduct Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable October 21, 2020

ASK
US
PHARMACOMPASS
Upload
your Marketing & Sales content
Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]
Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty
Post Enquiry
POST ENQUIRY